Federal Government Will not Pursue "Small Marijuana Cases"
Legalization Supported by 64% of the U.S. Population
Carlsbad, CA – March 14, 2018 - Is the Federal Government coming around to aknowledge the popular opinion in this Country? According to the latest statement from Jeff Sessions, yes: "Prosecutors will not pursue Small Marijuana Cases". This may also indicate the beginning of respecting State Laws, such as California, which has legalized medical and recreational marijuana. In fact, Sessions may have actually accelerated the process towards Federal legalization.

Broad Support
While the movement to legalize medical and recreational marijuana gains broader support by the day, the Federal Government is still catching up to popular opinion. Nevertheless, removing marijuana from "The Controlled Substance Act" as a Schedule 1 drug seems inevitable. Sixty-four (64%) of the U.S. population support broad legalization of marijuana in some form.
Support has Doubled
Thirty states and the District of Columbia currently have laws broadly legalizing marijuana in some form and 78% of the population in those States approve of the legalization for medical and/or recreational marijuana, more than double the support in 2000 .

Out of Step with Popular Opinion
Sessions and the Federal Government might find itself out of step not only with the majority of the US population, but also with Congress and his own Republican Party. Democrats support legalization by an astonishing 72%, while this year for the first time, a majority of Republicans also expresses support for legalizing marijuana; the current 51% support is up nine percentage points from  last year .
Data according to latest Gallup Pole
LiveWire Cultivation/Nursery Permit
LiveWire Ergogenics, Inc. (OTC: LVVV), being fully complying with California State law, has obtained a cannabis cultivation / nursery permit from the City of Coachella, California and has issued a purchase order to buy four greenhouses from GreenGro Technologies (OTC: GRNH).  LiveWire’s greenhouse facilities will be built to house a variety of cannabis strains, which the firm’s horticulturists will develop and grow for its clients. Each of the self-contained greenhouses is approximately 3,600 square feet, state-of-the-art and fully climate-controlled. As such, these greenhouses are key elements of LiveWire’s proprietary strain and cloning development and contracted cultivation strategy.

LiveWire Ergogenics plans to secure additional permits and licenses in order to accelerate its plan to establish legal and fully contained cannabis projects throughout the State of California. The Company believes that a tightly regulated market place will improve product quality and safety and will be to the benefit of operators and consumers alike.

For more information about LiveWire Ergogenics, visit http://www.livewireergogenics.com. For non-material updates, follow LiveWire Ergogenics on Twitter @livewireLVVV.
For more information about LiveWire Ergogenics visit www.livewireergogenics.com. or download the research report at www.swiresearch.com/report-index For non-material updates, follow LiveWire Ergogenics on Twitter @livewireLVVV.
About LiveWire Ergogenics, Inc.
LiveWire Ergogenics, Inc. (LVVV) specializes in identifying and monetizing current and future trends in the health and wellness industries, including the design and establishment of legal, fully controlled and contained cannabis production environments. To further this agenda, the Company is entering into select research partnerships to explore the application of cannabinoid-based products to target specific ailments or conditions with large “sufferer” populations, for human and veterinarian applications. This includes the development and licensing of high-quality cannabinoid-based products and services, the cloning of cannabis strains to produce positive medicinal results and the dosing verification of zero pesticide products for quality brands via its “7X-Pure Dosage and Verification System”. The team at LiveWire Ergogenics has a passion for research and advanced product development and is committed to generating and implementing innovative ideas to produce high-quality products that satisfy an increasing demand in this fast-growing industry.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and objectives of management for future operations, the development, regulatory approvals and commercialization of the Company’s products, or any of the Company’s other proposed products, systems or services. Such forward-looking statements are not meant to predict or guarantee actual results and performance, events or circumstances and actual events may differ considerably. Factors that may cause actual results to differ materially from any projections may include, without limitation, the Company’s inability to obtain additional financing, delays in the development of its products, the impact of significant new or changing government regulation in the cannabis industry, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

EquiNet, LLC
Toll free: 877-964-6463
Direct: 858-264-6500

1600 North Kraemer Blvd.
Anaheim, CA 92806
If you want to follow all other companies that we cover with more in depth research reports, go to our research site at www.swiresearch.com/report-index to download the reports,
or visit www.stockwatchindex.com for up to date news on the covered companies.
Please feel free to re-distribute the reports to your friends and colleagues.
We initiated coverage of LiveWire Ergogenics on August 16, 2017
StockWatchIndex and SWI Research (SWI) are not registered investment advisers and the information provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has been compensated with five million restricted shares (subject to the restrictions of rule 144) by the Company  for the dissemination of this and future releases and  for continuing consulting and advisory services. The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.